HER2-negative Clinical Trials in Jinan, Shandong
3 recruitingJinan, Shandong, China
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled296 locationsNCT06966700
Recruiting
Phase 2
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
HER2-negativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University77 enrolled29 locationsNCT06932068
Recruiting
Phase 4
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy
Locally Advanced Breast CancerHormone Receptor Positive，HER2-negative Breast Cancer
Yongsheng Wang100 enrolled1 locationNCT05809024